EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Cited by (1,066)

Items 801–900 of 1,066

1. A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer
   Kathy D. Miller, José Manuel Trigo, Catherine Wheeler, Alan Barge, Jacqui Rowbottom, George W. Sledge, Jose M Baselga · 2005 · Clinical Cancer Research
2. Targeted therapies for treatment of non‐small cell lung cancer—Recent advances and future perspectives
   Joan Minguet, Katherine Helen Smith, Peter Bramlage · 2015 · International Journal of Cancer
3. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
   Xueli Nan, Chao Xie, Xueyan Yu, Jie Liu · 2017 · Oncotarget
4. Cancer Drug Discovery and Development
   Jeffrey S. Humphrey, Karen Price, Elora Gupta, Andrew R. W. Baxter, John Bird, Daryl S. Sonnichsen, Joseph G. Naglich · 2003 · Humana Press eBooks
5. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor‐sensitizing and resistance mutations in the plasma DNA of patients with advanced non–small cell lung cancer during treatment with erlotinib
   Boe Sandahl Sørensen, Lin Wu, Wen Wei, Julie Tsai, Britta Weber, Ebba Nexø, Peter Meldgaard · 2014 · Cancer
6. Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non–Small-Cell Lung Cancer
   Eric B. Haura, Tawee Tanvetyanon, Alberto Chiappori, Charles C. Williams, George R. Simon, Scott Joseph Antonia, Jhanelle E. Gray, Sharon Litschauer, Leticia F. Tetteh, Anthony M. Neuger et al. · 2010 · Journal of Clinical Oncology
7. Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer
   Charles Andrew Butts, David Bodkin, Edward L. Middleman, Craig W. Englund, David H. Ellison, Yasmin Alam, Harvey Kreisman, Peter R. Graze, James F. Maher, Helen J. Ross et al. · 2007 · Journal of Clinical Oncology
8. Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
   Monika E. Hegi, Annie‐Claire Diserens, Pierre Bady, Yuta Kamoshima, Mathilde C.M. Kouwenhoven, Mauro Delorenzi, Wanyu L. Lambiv, Marie‐France Hamou, Matthias Sebastian Matter, Arend Koch et al. · 2011 · Molecular Cancer Therapeutics
9. Recent progress in TGF-β inhibitors for cancer therapy
   Zheng‐Yi Huang, Chih‐Ling Chung, Tsung‐Hui Hu, Jih‐Jung Chen, Pei‐Feng Liu, Chun‐Lin Chen · 2020 · Biomedicine & Pharmacotherapy
10. Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)
    Oscar G. Arrieta, Andrés Felipe Cardona, Claudio Marcelo Martin, Luis A. Mas, Luis Corrales, Guillermo Federico Bramuglia, O. Castillo, Matthew M. Meyerson, Eduardo Amieva-Rivera, Alma Delia Campos-Parra et al. · 2015 · Journal of Thoracic Oncology
11. Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non–Small Cell Lung Cancer Cell Line
    Atsuko Ogino, Hiroyuki Kitao, Seiki Hirano, Akiko Uchida, Masamichi Ishiai, Toshiyuki Kozuki, Nagio Takigawa, Minoru Takata, Katsuyuki Kiura, Mitsune Tanimoto · 2007 · Cancer Research
12. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib
    Triparna Sen, Pan Tong, Catherine Allison Stewart, Sandra Cristea, Aly Al-Amyn Valliani, David S. Shames, Abena B. Redwood, You Hong Fan, Lerong Li, Bonnie S. Glisson et al. · 2017 · Cancer Research
13. Increases of Amphiregulin and Transforming Growth Factor-α in Serum as Predictors of Poor Response to Gefitinib among Patients with Advanced Non–Small Cell Lung Cancers
    Nobuhisa Ishikawa, Yataro Daigo, Atsushi Takano, Masaya Taniwaki, Tatsuya Kato, Satoshi Hayama, Haruyasu Murakami, Yukio Takeshima, Kouki Inai, Hitoshi Nishimura et al. · 2005 · Cancer Research
14. STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments
    Sharon J. Diskin, Thomas Eck, Joel D. Greshock, Yaël P. Mossé, Tara L. Naylor, Christian J. Stoeckert, Barbara L. Weber, John M. Maris, Gregory R. Grant · 2006 · Genome Research
15. Epidermal Growth Factor Receptor Mutants from Human Lung Cancers Exhibit Enhanced Catalytic Activity and Increased Sensitivity to Gefitinib
    Mulloy, Roseann, Ferrand, Audrey, Kim, Youngjoo, Sordella, Raffaella, Bell, Daphne W., Haber, Daniel A., Anderson, Karen S., Settleman, Jeffrey · 2007 · Cancer Research
16. Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent
    Chris M.J. Conklin, Kenneth J. Craddock, Cherry L. Have, Janessa J. Laskin, Christian Couture, Diana N. Ionescu · 2012 · Journal of Thoracic Oncology
17. The Role of STAT3 in Non-Small Cell Lung Cancer
    Daijiro Harada, Nagio Takigawa, Katsuyuki Kiura · 2014 · Cancers
18. The Epidermal Growth Factor Receptor: A Role in Repair of Radiation-Induced DNA Damage
    David J. Chen, Chaitanya S. Nirodi · 2007 · Clinical Cancer Research
19. Molecular basis for multimerization in the activation of the epidermal growth factor receptor
    Yongjian Huang, Shashank Bharill, Deepti Karandur, Sean M. Peterson, Morgan Marita, Xiaojun Shi, Megan J. Kaliszewski, Adam W. Smith, Ehud Y. Isacoff, John Kuriyan · 2016 · eLife
20. cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth
    Zirong Chen, Jian‐Liang Li, Shuibin Lin, Chunxia Cao, Nicholas T. Gimbrone, Rongqiang Yang, Dongtao Fu, Miranda B. Carper, Eric B. Haura, Matthew B. Schabath et al. · 2016 · Journal of Clinical Investigation
21. Perturbation Biology: Inferring Signaling Networks in Cellular Systems
    Evan J. Molinelli, Anil Korkut, Weiqing Wang, Martin L. Miller, Nicholas Paul Gauthier, Xiaohong Jing, Poorvi Kaushik, Qin He, Gordon Brent Mills, David B. Solit et al. · 2013 · PLoS Computational Biology
22. Genetic Changes in Squamous Cell Lung Cancer: A Review
    Rebecca Suk Heist, Lecia Van Dam Sequist, Jeffrey A. Engelman · 2012 · Journal of Thoracic Oncology
23. Activation of notch‐1 enhances epithelial–mesenchymal transition in gefitinib‐acquired resistant lung cancer cells
    Mian Xie, Li Zhang, Chaosheng He, Fei Xu, Junling Liu, Zhihuang Hu, Liping Zhao, Ying Tian · 2011 · Journal of Cellular Biochemistry
24. The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients
    Lecia Van Dam Sequist, Sunitha Nagrath, Mehmet Toner, Daniel A. Haber, Thomas James Lynch · 2009 · Journal of Thoracic Oncology
25. Maternal Embryonic Leucine Zipper Kinase/Murine Protein Serine-Threonine Kinase 38 Is a Promising Therapeutic Target for Multiple Cancers
    Daniel Gray, Adrian M. Jubb, Deborah A. Hogue, Patrick Dowd, Noelyn M. Kljavin, Sothy Yi, Wei Bai, Gretchen D. Frantz, Zemin Zhang, Hartmut Koeppen et al. · 2005 · Cancer Research
26. Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
    Cabanos, Heidie Frisco, Hata, Aaron N. · 2021 · Cancers
27. ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas
    Lynette Marie Sholl, Heather H. Sun, Mohit Butaney, Chengsheng Zhang, Charles Lee, Pasi Antero Janne, Scott J. Rodig · 2013 · The American Journal of Surgical Pathology
28. MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells
    Kazuhiro Kitamura, Masahiro Seike, Tetsuya Okano, Kuniko Matsuda, Akihiko Miyanaga, Hideaki Mizutani, Rintaro Noro, Yuji Minegishi, Kaoru Kubota, Akihiko Gemma · 2013 · Molecular Cancer Therapeutics
29. Minimally Invasive Pharmacokinetic and Pharmacodynamic Technologies in Hypothesis-Testing Clinical Trials of Innovative Therapies
    Paul Workman, Eric Ofori Aboagye, Yuen‐Li Chung, John Richard Griffiths, Rachel Hart, Martin O. Leach, Ross J. Maxwell, Paul M.J. McSheehy, Pat Price, Jamal Zweit · 2006 · JNCI Journal of the National Cancer Institute
30. Nuclear Translocation of Epidermal Growth Factor Receptor by Akt-dependent Phosphorylation Enhances Breast Cancer-resistant Protein Expression in Gefitinib-resistant Cells
    Wei‐Chien Huang, Yun‐Ju Chen, Long‐Yuan Li, Y WEI, Sheng-Chieh Hsu, Shing-Ling Tsai, Pei-Chun Chiu, Wei‐Pang Huang, Ying‐Nai Wang, Chung‐Hsuan Chen et al. · 2011 · Journal of Biological Chemistry
31. Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations
    Satoshi Morita, Isamu Okamoto, Kunihiko Kobayashi, Koichi Yamazaki, Hajime Asahina, Akira Inoue, Koichi Hagiwara, Noriaki Sunaga, Noriko Yanagitani, Toyoaki Hida et al. · 2009 · Clinical Cancer Research
32. Detection ofEGFRGene Mutation in Lung Cancer by Mutant-Enriched Polymerase Chain Reaction Assay
    Hiroaki Asano, Shinichi Toyooka, Masaki Tokumo, Kouichi Ichimura, Keisuke Aoe, Sachio Ito, Kazunori Tsukuda, Mamoru Ouchida, Motoi Aoe, Hideki Katayama et al. · 2006 · Clinical Cancer Research
33. Stress-Induced EGFR Trafficking: Mechanisms, Functions, and Therapeutic Implications
    Jay Xiaojun Tan, Paul F. Lambert, Alan C. Rapraeger, Richard Allen Anderson · 2016 · Trends in Cell Biology
34. Epidermal Growth Factor–Independent Transformation of Ba/F3 Cells with Cancer-Derived Epidermal Growth Factor Receptor Mutants Induces Gefitinib-Sensitive Cell Cycle Progression
    Jingrui Jiang, Heidi E. Greulich, Pasi Antero Janne, William R. Sellers, Matthew M. Meyerson, James D. Griffin · 2005 · Cancer Research
35. Practical Management of Patients With Non–Small-Cell Lung Cancer Treated With Gefitinib
    Neelam T. Shah, Mark G. Kris, William J. Pao, Leslie B. Tyson, Barbara A. Pizzo, Murk-Hein Heinemann, Leah Ben‐Porat, Dana L. Sachs, Robert T. Heelan, Vincent A. Miller · 2004 · Journal of Clinical Oncology
36. Methodological and practical challenges for personalized cancer therapies
    Ignacio Ivan Wistuba, Juri George Gelovani, Jörg J. Jacoby, Suzanne E. Davis, Roy S. Herbst · 2011 · Nature Reviews Clinical Oncology
37. Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy
    Gur Pines, Wolfgang J. Köstler, Yosef Yarden · 2010 · FEBS Letters
38. Lung Cancer in the Era of Precision Medicine
    Katerina A. Politi, Roy S. Herbst · 2015 · Clinical Cancer Research
39. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis
    Nikolas Hendrik Stoecklein, Christoph A. Klein · 2009 · International Journal of Cancer
40. A Rapid, Sensitive Assay to Detect EGFR Mutation in Small Biopsy Specimens from Lung Cancer
    Yasushi Yatabe, Toyoaki Hida, Yoshitsugu Horio, Takayuki Kosaka, Takashi Takahashi, Tetsuya Mitsudomi · 2006 · Journal of Molecular Diagnostics
41. Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China
    Yi-Long Lung Cancer Wu, Wen‐Zhao Zhong, Long-Yun Li, Xiao-Tong Zhang, Li Zhang, Cai-Cun Zhou, Wei Liu, Bin Jiang, Xin-Lin Mu, Jia-Ying Lin et al. · 2007 · Journal of Thoracic Oncology
42. EGFR Signaling in Colorectal Carcinoma
    Alyssa M. Krasinskas · 2011 · Pathology Research International
43. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond
    Sai‐Hong Ignatius Ou · 2011 · Drug Design Development and Therapy
44. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
    Cragg, Mark S., Harris, Claire, Strasser, Andreas, Scott, Clare L. · 2009 · Nature Reviews Cancer
45. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.
    Cortot, Alexis B., Repellin, Claire E., Shimamura, Takeshi, Capelletti, Marzia, Zejnullahu, Kreshnik, Ercan, Dalia, Christensen, James G., Wong, Kwok-Kin, Gray, Nathanael S., Jänne, Pasi A. · 2013 · Cancer Research
46. Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer
    Soundararajan Krishnaswamy, Rajani Kanteti, Jonathan S. Duke‐Cohan, Sivakumar Loganathan, Wanqing Liu, Patrick C. Ma, Martin Sattler, Patrick A. Singleton, Nithya Ramnath, Federico Innocenti et al. · 2009 · Clinical Cancer Research
47. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology
    Amit J. Sabnis, Trever Grant Bivona · 2019 · Trends in Molecular Medicine
48. Validation of a Next-Generation Sequencing Assay for Clinical Molecular Oncology
    Catherine E. Cottrell, Hussam Al‐Kateb, Andrew J. Bredemeyer, Eric James Duncavage, David H. Spencer, Haley Abel, Christina M. Lockwood, Ian S. Hagemann, Stephanie M. O’Guin, Lauren C. Burcea et al. · 2013 · Journal of Molecular Diagnostics
49. Frequency of and variables associated with the EGFR mutation and its subtypes
    Tomoaki Tanaka, Masaru Matsuoka, Akihisa Sutani, Akihiko Gemma, Makoto Maemondo, Akira Inoue, Shoji Okinaga, Makoto Nagashima, Satoshi Oizumi, Kazutsugu Uematsu et al. · 2009 · International Journal of Cancer
50. Lung cancer in never smokers: Disease characteristics and risk factors
    Athanasios G. Pallis, Konstantinos Nikolaos Syrigos · 2013 · Critical Reviews in Oncology/Hematology
51. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
    Bin-Chi Liao, Jih‐Hsiang Lee, Chia‐Chi Lin, Ya‐Fang Chen, Chin‐Hao Chang, Chao‐Chi Ho, Jin‐Yuan Shih, Chong‐Jen Yu, James Chih‐Hsin Yang · 2015 · Journal of Thoracic Oncology
52. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence
    Ou, Sai-Hong Ignatius · 2012 · Critical Reviews in Oncology/Hematology
53. Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells
    Zhenfeng Zhang, Susumu S. Kobayashi, Alain Borczuk, Rom S. Leidner, Thomas LaFramboise, Alan D. Levine, Balázs Halmos · 2010 · Carcinogenesis
54. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience
    Maria Clemence Schwaederle, Barbara A. Parker, Richard B. Schwab, Gregory A. Daniels, David Eric Piccioni, Santosh Kesari, Teresa L. Helsten, Lyudmila A. Bazhenova, Julio Romero, Paul Timothy Fanta et al. · 2016 · Molecular Cancer Therapeutics
55. Phase II Trial of Cetuximab in Patients With Previously Treated Non–Small-Cell Lung Cancer
    Nasser H. Hanna, Rogério Lilenbaum, Rafat Ansari, Thomas James Lynch, Ramaswamy Govindan, Pasi Antero Janne, Philip Bonomi · 2006 · Journal of Clinical Oncology
56. Differential Constitutive Activation of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cells Bearing EGFR Gene Mutation and Amplification
    Takafumi Okabe, Isamu Okamoto, Kenji Tamura, Masaaki Terashima, Takeshi Yoshida, Taroh Satoh, Minoru Takada, Masahiro Fukuoka, Kazuhiko Nakagawa · 2007 · Cancer Research
57. Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
    Jänne, Pasi A., Boss, David S., Camidge, D. Ross, Britten, Carolyn D., Engelman, Jeffrey A., Garon, Edward B., Guo, Feng, Wong, Steven, Liang, Jane, Letrent, Stephen et al. · 2011 · Clinical Cancer Research
58. Frequent EGFR mutations in brain metastases of lung adenocarcinoma
    Shingo Matsumoto, Kenji Takahashi, Reika Iwakawa, Yoshihiro Matsuno, Yukihiro Nakanishi, Takashi Kohno, Eiji Shimizu, Jun Yokota · 2006 · International Journal of Cancer
59. Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study
    Alex Y. Chang, Purvish Mahendra Parikh, Sumitra Thongprasert, Eng Huat Tan, Reury-Perng Perng, Domingo Ganzon, Chih-Hsin Yang, Chao‐Jung Tsao, Claire L Watkins, N. Botwood et al. · 2006 · Journal of Thoracic Oncology
60. Cellular responses to EGFR inhibitors and their relevance to cancer therapy
    Pinaki R Dutta, Amit M. Maity · 2007 · Cancer Letters
61. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
    Ying Cheng, Haruyasu Murakami, Pan‐Chyr Yang, Jianxing He, Kazuhiko Nakagawa, Jin Hyoung Kang, Joo-Hang Kim, Xin Wang, Sotaro Enatsu, Tarun Puri et al. · 2016 · Journal of Clinical Oncology
62. Icotinib versus whole-brain irradiation in patients with EGFR -mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial
    Jin‐Ji Yang, Caicun Zhou, Yi-Sheng Huang, Jifeng Feng, Lu Sun, Yong Song, Cheng Huang, Gang Wu, Li Zhang, Ying Cheng et al. · 2017 · The Lancet Respiratory Medicine
63. Mutational analysis of the <i>HER2</i> gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features
    Buttitta, Fiamma, Barassi, Fabio, Fresu, Giuseppina, Felicioni, Lara, Chella, Antonio, Paolizzi, Diego, Lattanzio, Giuseppe, Salvatore, Simona, Camplese, Pier P., Rosini, Sandra et al. · 2006 · International Journal of Cancer
64. ALK inhibitors in the treatment of advanced NSCLC
    Cesare Gridelli, Solange Peters, Assunta Sgambato, Francesca Casaluce, Alex A. Adjei, Fortunato Ciardiello · 2013 · Cancer Treatment Reviews
65. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: Molecular bases for EGFR-targeted therapy
    Pablo Uribe, Sergio González · 2011 · Pathology - Research and Practice
66. Switching on kinases: oncogenic activation of BRAF and the PDGFR family
    Nick J. Dibb, Stephen M. Dilworth, Clifford D. Mol · 2004 · Nature reviews. Cancer
67. Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy
    Lee, Dae Ho, Park, Keunchil, Kim, Joo Hang, Lee, Jong-Seok, Shin, Sang Won, Kang, Jin-Hyoung, Ahn, Myung-Ju, Ahn, Jin Seok, Suh, Cheolwon, Kim, Sang-We · 2010 · Clinical Cancer Research
68. Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase
    Ludovico Sutto, Francesco Luigi Gervasio · 2013 · Proceedings of the National Academy of Sciences
69. Molecular and cellular biology of neuroendocrine lung tumors: Evidence for separate biological entities
    Dorian R.A. Swarts, Frans C. S. Ramaekers, Ernst‐Jan M. Speel · 2012 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
70. The Development of HKI‐272 and Related Compounds for the Treatment of Cancer
    Allan Wissner, Tarek S. Mansour · 2008 · Archiv der Pharmazie
71. Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST
    Mizuki Nishino, Jyothi Priya Jagannathan, Katherine Maragaret Krajewski, Kevin N. O'Regan, Hiroto Hatabu, Geoffrey Ira Shapiro, Nikhil H. Ramaiya · 2012 · American Journal of Roentgenology
72. EGFR-targeted anti-cancer drugs in radiotherapy: Preclinical evaluation of mechanisms
    Michael A. Baumann, Mechthild Krause, Ekkehard Dikomey, Klaus Dittmann, Wolfgang Dörr, Ulla Kasten-Pisula, H. Peter Rodemann · 2007 · Radiotherapy and Oncology
73. A framework for identification of actionable cancer genome dependencies in small cell lung cancer
    Martin L. Sos, Felix Dietlein, Martin Peifer, Jakob Schöttle, Hyatt Balke‐Want, Christian Müller, Mirjam Koker, André Richters, Stefanie Heynck, Florian Malchers et al. · 2012 · Proceedings of the National Academy of Sciences
74. The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
    Young-Wook Kim, Jeonghun Ko, Zheng-Yun Cui, Amir Abolhoda, Jin Seok Ahn, Sai-Hong Ou, Myung‐Ju Ahn, Keunchil Park · 2012 · Molecular Cancer Therapeutics
75. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
    Masayuki Takeda, Isamu Okamoto, Kazuhiko Nakagawa · 2015 · Lung Cancer
76. Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors
    Shigenari Nukaga, Hiroyuki Yasuda, Katsuya Tsuchihara, Junko Hamamoto, Keita Masuzawa, Ichiro Kawada, Katsuhiko Naoki, Shingo Matsumoto, Sachiyo Mimaki, Shinnosuke Ikemura et al. · 2017 · Cancer Research
77. Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: Comparison between T790M mutation‐positive and mutation‐negative populations
    Hata, Akito, Katakami, Nobuyuki, Yoshioka, Hiroshige, Takeshita, Jumpei, Tanaka, Kosuke, Nanjo, Shigeki, Fujita, Shiro, Kaji, Reiko, Imai, Yukihiro, Monden, Kazuya et al. · 2013 · Cancer
78. Digital PCR analysis of circulating nucleic acids
    Irena Hudecova · 2015 · Clinical Biochemistry
79. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib
    Mary E. Irwin, Kelly L. Mueller, Natacha Bohin, Yubin Ge, Julie L. Boerner · 2010 · Journal of Cellular Physiology
80. Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non–Small-Cell Lung Cancer
    George R. Simon, Anupama Sharma, Xueli Li, Todd Richard Hazelton, Frank W. Walsh, Charles C. Williams, Alberto Chiappori, Eric B. Haura, Tawee Tanvetyanon, Scott Joseph Antonia et al. · 2007 · Journal of Clinical Oncology
81. Noninvasive Saliva-based EGFR Gene Mutation Detection in Patients with Lung Cancer
    Fang Wei, Chien‐Chung Lin, Aron Y. Joon, Ziding Feng, Gabriel E. Troche, Maruja E. Lira, David Chia, Mao Mao, Chung‐Liang Ho, Wu‐Chou Su et al. · 2014 · American Journal of Respiratory and Critical Care Medicine
82. Catalytic Mechanisms and Regulation of Protein Kinases
    Zhihong Wang, Philip A. Cole · 2014 · Methods in enzymology on CD-ROM/Methods in enzymology
83. Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel
    Ayana Sawai, Sarat Chandarlapaty, Heidi E. Greulich, Mithat Gönen, Qing Ye, Carlos L. Arteaga, William R. Sellers, Neal X. Rosen, David B. Solit · 2008 · Cancer Research
84. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
    Carol A. Townsley, Pierre P Major, Lillian L. Siu, Janet Ellen Dancey, ELAINE CHEN, Gregory R. Pond, Trudey Nicklee, Jcm Ho, David William Hedley, Ming‐Sound Tsao et al. · 2006 · British Journal of Cancer
85. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results
    Michael A. Baumann, Mechthild Krause · 2004 · Radiotherapy and Oncology
86. Single-cell morphology encodes metastatic potential
    Wu, Pei-Hsun, Gilkes, Daniele M., Phillip, Jude M., Narkar, Akshay, Cheng, Thomas Wen-Tao, Marchand, Jorge, Lee, Meng-Horng, Li, Rong, Wirtz, Denis · 2020 · Science Advances
87. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer.
    Su, Zengliu, Dias-Santagata, Dora, Duke, MarKeesa, Hutchinson, Katherine, Lin, Ya-Lun, Borger, Darrell R., Chung, Christine H., Massion, Pierre P., Vnencak-Jones, Cindy L., Iafrate, A. John et al. · 2011 · The Journal of Molecular Diagnostics
88. The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations
    Heon, Stephanie, Yeap, Beow Y., Lindeman, Neal I., Joshi, Victoria A., Butaney, Mohit, Britt, Gregory J., Costa, Daniel B., Rabin, Michael S., Jackman, David M., Johnson, Bruce E. · 2012 · Clinical Cancer Research
89. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer
    Bing Li, Shengxiang Ren, Xuefei Li, Yongsheng Wang, David H. Garfield, Songwen Zhou, Xiaoxia Chen, Chunxia Su, Mo Chen, Peng Kuang et al. · 2013 · Lung Cancer
90. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors
    John Lindsay Marshall · 2006 · Cancer
91. Role of tumor markers in patients with solid cancers: A critical review
    Michael Joe Duffy · 2007 · European Journal of Internal Medicine
92. Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinomas: Relationship with CT Characteristics and Histologic Subtypes
    Hyun-Ju Lee, Young Tae Kim, Chang Hyun Kang, Binsheng Zhao, Yongqiang Tan, Lawrence Howard Schwartz, Thorsten Persigehl, Yoon Kyung Jeon, Doo Hyun Chung · 2013 · Radiology
93. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine
    Shuji Ogino, Charles S. Fuchs, Edward L. Giovannucci · 2012 · Expert Review of Molecular Diagnostics
94. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
    Yang, J J, Zhou, Q, Yan, H H, Zhang, X C, Chen, H J, Tu, H Y, Wang, Z, Xu, C R, Su, J, Wang, B C et al. · 2017 · British Journal of Cancer
95. Anticipating the 1,000 dollar genome.
    Elaine R. Mardis · 2006 · Genome biology
96. Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors
    Satoshi Sogabe, Youichi Kawakita, Shigeru Igaki, Hidehisa Iwata, Hiroshi Miki, Douglas R. Cary, Terufumi Takagi, Shinji Takagi, Yoshikazu Ohta, Tomoyasu Ishikawa · 2012 · ACS Medicinal Chemistry Letters
97. Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis
    Yang Zhang, Yihua Sun, Yunjian Pan, Chenguang Li, Lei Shen, Yuan Li, Xiaoyang Luo, Ting Ye, Rui Wang, Haichuan Hu et al. · 2012 · Clinical Cancer Research
98. Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS
    Grzegorz J. Korpanty, Donna M. Graham, Mark David Vincent, Natasha B. Leighl · 2014 · Frontiers in Oncology
99. Pharmacogenetics in drug discovery and development: a translational perspective
    Allen D. Roses · 2008 · Nature Reviews Drug Discovery
100. Targeting ALK in neuroblastoma—preclinical and clinical advancements
     Erica L. Carpenter, Yaël P. Mossé · 2012 · Nature Reviews Clinical Oncology